首页> 外文期刊>Journal of interventional cardiology >Comparison of three-year clinical outcomes with nonextended versus extended dual antiplatelet therapy between first- and second-generation drug-eluting stent implantation in patients with acute myocardial infarction: Data from the infarct prognosis study registry
【24h】

Comparison of three-year clinical outcomes with nonextended versus extended dual antiplatelet therapy between first- and second-generation drug-eluting stent implantation in patients with acute myocardial infarction: Data from the infarct prognosis study registry

机译:急性心肌梗死患者第一代和第二代药物洗脱支架植入术与非扩展和扩展双重抗血小板治疗的三年临床结果比较:梗死预后研究注册数据

获取原文
获取原文并翻译 | 示例
           

摘要

Background: The difference of the clinical outcomes between nonextended (≤12 months) and extended (>12 months) dual antiplatelet therapy (DAPT) remains unclear in patients with acute myocardial infarction (AMI) implanted by different generations of drug-eluting stent (DES). Methods: We identified 790 consecutive patients with AMI who were free from major adverse cardiac events for 12 months after first-generation (n = 537) or second-generation DES (n = 253) implantation; each DES generation group was further divided into nonextended and extended DAPT. Results: During follow-up (median: 40 months), nonextended DAPT in the first-generation DES group showed a higher rate of cardiac death or MI than was observed in the extended DAPT group (14% vs 2%, P < 0.001). However, in the second-generation DES group, there was no difference in the occurrence of cardiac death and MI between the extended and nonextended groups (4% vs 3%, P = 0.809). Nonextended DAPT was the most significant predictor of cardiac death and MI for first-generation DES implantation [hazard ratio (HR) = 5.47, 95% confidence interval (CI) = 1.53-19.59, P = 0.009] but not for second-generation DES implantation [HR = 3.21, 95% CI = 0.21-50.65, P = 0.401]. Conclusion: This study suggested that the clinical outcomes between nonextended and extended DAPT might be different depending on the generation of implanted DESs in patients with AMI.
机译:背景:对于不同世代药物洗脱支架(DES)植入的急性心肌梗死(AMI)患者,未延长(≤12个月)和延长(> 12个月)双重抗血小板治疗(DAPT)的临床结局差异尚不清楚)。方法:我们确定了790例连续的AMI患者,他们在植入第一代(n = 537)或第二代DES(n = 253)后的12个月内没有发生严重的不良心脏事件;每个DES生成组进一步分为非扩展DAPT和扩展DAPT。结果:在随访中(中位数:40个月),第一代DES组未延长的DAPT表现出比延长的DAPT组更高的心源性死亡或MI发生率(14%比2%,P <0.001) 。但是,在第二代DES组中,延长组和未延长组之间的心源性死亡和MI发生率没有差异(4%vs 3%,P = 0.809)。对于第一代DES植入,未扩展的DAPT是心源性死亡和心梗的最重要预测指标[风险比(HR)= 5.47,95%置信区间(CI)= 1.53-19.59,P = 0.009],但对于第二代DES则不是植入[HR = 3.21,95%CI = 0.21-50.65,P = 0.401]。结论:这项研究表明,未扩展DAPT和扩展DAPT之间的临床结局可能因AMI患者植入DES的产生而有所不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号